Ruben Krupik
Ruben Krupik is an experienced entrepreneur, with a comprehensive understanding of the complex processes involved in the transformation of an idea into a prospering operation as exemplified in several successful start-up companies in medical technology (Given Imaging, Galil Medical), image processing (3DV), broadband (V-Soft and Witcom) and other fields which he co-founded. As CEO of ARTE, Ruben Krupik is responsible for the strategic management of biomedical investments owned by a variety of investors specifically, Clal Biotechnology Industries and the Arison Group, as well as other biotechnology, medical device and life sciences related holdings. Under this capacity Ruben Krupik acts as active chairman of the Board of Directors for Steps Ventures, and as a board member for several leading Israeli companies (Compugen, Ham-Let, Valor, and more). Prior thereto, he founded and headed RDC (Rafael Development Corporation), a joint venture between Rafael and Discount Investments. RDC sought and identified the commercial potential of different Rafael’s technologies, and developed these ideas into successful technology companies. Prior to RDC, Mr. Krupik held various executive positions in Tadiran Communications. Ruben Krupik holds LL.B. degree from the Faculty of Law, Tel Aviv University, Tel Aviv, Israel and B.A. in Economics and Political Science from the Hebrew University in Jerusalem, Israel.

Ofer Gonen
Ofer Gonen is the VP, for Business Development of the ARTE group and focuses on the day-to-day management of biomedical investments owned by a variety of investors like Teva, the Arison Group and the Abramson Group as well as other biotechnology, medical device and life sciences related holdings. Ofer Gonen serves as a vice president in Clal Biotechnology Industries, the largest life sciences investment fund in Israel. Under this capacity he acts as an executive board member of several portfolio companies (Gamida-Cell, Colbar, TransPharma, Polyheal, CureTech, MediWound). Prior thereto he was a technology consultant for various Israeli venture capital funds and served as the Academic Aide to the Governor of the Bank of Israel. Mr. Gonen has gained extensive experience in R&D and project management in defense oriented projects for which he was awarded the Israeli National Security Medal. Mr. Gonen holds M.Sc. degree in Computer Science, M.A. magna cum laude in Economics and Finance from Tel Aviv University and B.Sc. magna cum laude in Physics, Mathematics and Chemistry from the Hebrew University in Jerusalem, Israel.

Tamar Manor, PhD
Dr. Manor brings to CureTech a combination of business and financial perspective with profound scientific knowledge. Currently, Dr. Manor is the CTO for Biotechnology at Clal Industries and Investments (CII) responsible for the investment portfolio of CII and CBI, which includes 12 biotechnology and medical device companies, covering a diverse range of products. Prior thereto between 1999 to 2002, Dr. Manor was the Manager for Pre-clinical and Clinical Affairs at Vital Medical Ltd. where she provided the liaison between science and applicable medical, biomedical and engineering. Before that, she spent over 15 years in leading research groups at Bar-Ilan and Tel-Aviv universities specializing in neurobiology, physiology and pathology. Dr. Manor holds a Ph.D. in neurophysiology from Bar-Illan University, Israel. She is a member of the Israeli association for planning and control of clinical trials, the Israeli Society for Neurosciences and the Society of Neuroscience.